![](https://ml.globenewswire.com/media/aba52262-f4b6-4253-9fac-9e7a125c04b7/small/olema-oncology-high-res-logo-png.png)
Olema Oncology to Present New Palazestrant Clinical Data in Combination with CDK4/6 Inhibitors at the 2023 San Antonio Breast ...
Presentations detailing initial Phase 1b clinical data for palazestrant in combination with ribociclib, a Poster Spotlight Session on Phase 2 clinical data for palazestrant in combination with palbociclib, and the OPERA-01 Phase 3 clinical trial in …